Modern approaches of the diagnostics and treatment of cervical cancer

15 травня 2020
927
Спеціальності :
Резюме

Objective — to determine the features of the application of new approaches to the management and treatment of patients with cervical cancer (CC), taking into account the stage of the disease, the main prognostic factors and the spread of the disease, and to the management of patients with recurrent disease and the fertility-sparing treatment of reproductive age women. Object and methods. 2015–2020 scientific publications (PubMed Search), data of the patients with CC who treated at the National cancer institute (Kyiv), clinical guidelines for the management of patients with malignancies of the European Society for Medical Oncology (ESMO) 2016, clinical guidelines for the management of patients with CC of the European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology (ESGO)/ESTRO/ESP) 2018 had been investigated. Results and conclusions. Today the main prognostic factors of CC have been formed, which allow to make a plan of management of patients and to choose an adequate treatment. Diagnostic examination of lymph nodes and distant metastases for CC is mandatory. The main methods of treatment for patients with CC are surgical treatment and radiation therapy. Surgical treatment is more commonly used to the initial stages of CC but radiation therapy is more commonly used to advanced cancer. At the present time, approaches of the management and treatment of women of reproductive age who wish to preserve fertility and pregnant women with CC have an important role.

References:

  • Aghili M., Andalib B., Karimi Moghaddam Z. et al. (2018) Concurrent Chemo- Radiobrachytherapy with Cisplatin and Medium Dose Rate Intra-Cavitary Brachytherapy for Locally Advanced Uterine Cervical Cancer. Asian Pac. J. Cancer Prev., 19(10): 2745–2750. DOI: 10.22034/APJCP.2018.19.10.2745.
  • Amant F., Berveiller P., Boere I.A. et al. (2019) Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann. Oncol., 30(10): 1601–1612. DOI: 10.1093/annonc/mdz228.
  • Beharee N., Shi Z., Wu D. et al. (2019) Diagnosis and treatment of cervical cancer in pregnant women. Cancer Med., 8(12): 5425–5430. DOI: 10.1002/cam4.2435.
  • Bourgioti C., Konidari M., Moulopoulos L.A. (2019) Imaging of Gynecologic Malignancy in a Reproductive Age Female: Cancer During Pregnancy. Radiol. Clin. North Am., 58(2): 413–430. DOI: 10.1016/j.rcl.2019.10.008.
  • Boussios S., Seraj E., Zarkavelis G. et al. (2016) Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit. Rev. Oncol. Hematol., 108: 164–174. DOI: 10.1016/j.critrevonc.2016.11.006.
  • Căpîlna M.E., Szabo B., Becsi J., Ioanid N. et al. (2016) Radical Trachelectomy Performed During Pregnancy: A Review of the Literature. Int. J. Gynecol. Cancer, 26(4): 758–762. DOI: 10.1097/IGC.0000000000000655.
  • Cibula D., Pötter R., Planchamp F. et al. (2018) The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Arch., 472(6): 919–936. DOI: 10.1007/s00428-018-2362-9.
  • Datta N.R., Stutz E., Liu M. et al. (2017) Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis. Gynecol. Oncol., 145(2): 374–385. DOI: 10.1016/j.ygyno.2017.01.033.
  • El-Zein M., Richardson L., Franco E.L. (2017) Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J. Clin. Virol., 76 Suppl. 1: S62–S68. DOI: 10.1016/j.jcv.2015.11.020.
  • ESMO Guidelines Gynaecological Malignancies (2016) Cervical cancer, 29–36 p.
  • Espenel S., Garcia M.A., Langrand-Escure J. et al. (2019) Special Focus on Stage IV Cervical Cancer Patients: A Decade Experience. Oncology, 97(3): 125–134. DOI: 10.1159/000500025.
  • Fedorenko Z., Michailovich Y., Goulak L. et al. (2018) Cancer in Ukraine, 2017–2018. Bulletin National Cancer Registry of Ukraine, 20: 44–45.
  • Gianino M.M., Lenzi J., Bonaudo M., Fantini M.P. et al. (2018) Organized screening programmes for breast and cervical cancer in 17 EU countries: trajectories of attendance rates. BMC Public Health, 18(1): 1236. DOI: 10.1186/s12889-018-6155-5.
  • Godoy-Ortiz A., Plata Y., Alcaide J. et al. (2018) Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in «real world» patients. Clin. Transl. Oncol., 20(7): 922–927. DOI: 10.1007/s12094-017-1808-x.
  • Han Y., Wu L.Y., Li N. et al. (2017) Clinical Analysis of Surgery for Recurrent Cervical Cancer: A Review of 45 Cases. Zhonghua Zhong Liu Za Zhi., 39(5): 369–373. DOI: 10.3760/cma.j.issn.0253-3766.2017.05.010.
  • Hillemanns P., Brucker S., Holthaus B. et al. (2018) Comment on the LACC Trial Investigating Early-stage Cervical Cancer by the Uterus Commission of the Study Group for Gynecologic Oncology (AGO) and the Study Group for Gynecologic Endoscopy (AGE) of the German Society for Gynecology and Obstetrics (DGGG). Geburtshilfe Frauenheilkd., 78(8): 766–767. DOI: 10.1055/a-0655-8112.
  • Isidean S.D., Wang Y., Mayrand M.H. et al. (2019) Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening. Int. J. Cancer, 144(10): 2408–2418. DOI: 10.1002/ijc.31970.
  • Kim H., Cho W.K., Kim Y.J. et al. (2020) Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy. Gynecol. Oncol., pii: S0090-8258(20)30177-3. DOI: 10.1016/J.YGYNO.2020.02.031.
  • Kim J.H., Kim D.Y., Suh D.S. et al. (2018) The efficacy of sentinel lymph node mapping with indocyanine green in cervical cancer. World J. Surg Oncol., 16(1): 52. DOI: 10.1186/s12957-018-1341-6.
  • Kim M., Ishioka S., Endo T. et al. (2016) Possibility of less radical treatment for patients with early invasive uterine cervical cancer. J. Obstet. Gynaecol. Res., 42(7): 876–882. DOI: 10.1111/jog.12980.
  • Kim S.W., Chun M., Ryu H.S. et al. (2017) Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy. BMC Cancer., 17(1): 297. DOI: 10.1186/s12885-017-3299-0.
  • Korenaga T.K., Tewari K.S. (2020) Gynecologic cancer in pregnancy. Gynecol. Oncol., pii: S0090-8258(20)30231-6. DOI: 10.1016/j.ygyno.2020.03.015.
  • Laifer-Narin S.L., Genestine W.F., Okechukwu N.C. et al. (2018) The Role of Computed Tomography and Magnetic Resonance Imaging in Gynecologic Oncology. PET Clin., 13(2): 127–141. DOI: 10.1016/j.cpet.2017.11.002.
  • Ma J., Yu L., Xu F. et al. (2019) Treatment and clinical outcomes of cervical cancer during pregnancy. Ann. Transl. Med., 7(11): 241. DOI: 10.21037/atm.2019.04.76.
  • Mabuchi S., Isohashi F., Okazawa M. et al. (2017) Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients. J. Gynecol. Oncol., 28(1): e15. DOI: 10.3802/jgo.2017.28.e15.
  • Matsuo K., Machida H., Mandelbaum R.S. et al. (2018) Validation of the 2018 FIGO cervical cancer staging system. Gynecol. Oncol., 152(1): 87–93. DOI: 10.1016/j.ygyno.2018.10.026.
  • Mittal P., Chopra S., Pant S. et al. (2018) Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance-Based Brachytherapy? J. Glob. Oncol., 4: 1–9. DOI: 10.1200/JGO.18.00028.
  • Nakao Y., Tamauchi S., Yoshikawa N. et al. (2020) Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy. Case Rep. Oncol., 13(1): 373–378. DOI: 10.1159/000506446.
  • Ning M.S., Ahobila V., Jhingran A. et al. (2018) Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol. Oncol., 148(1): 132–138. DOI: 10.1016/j.ygyno.2017.10.017.
  • Pecorelli S. (2009a) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet., 105: 103–104.
  • Pecorelli S., Zigliani L., Odicino F. (2009b) Revised FIGO staging for carcinoma of the cervix. Int. J. Gynaecol. Obstet., 105(2): 107–108. doi: 10.1016/j.ijgo.2009.02.009.
  • Perrone A.M., Bovicelli A., D’Andrilli G. et al. (2019) Cervical cancer in pregnancy: Analysis of the literature and innovative approaches. J. Cell Physiol., 234(9): 14975–14990. DOI: 10.1002/jcp.28340.
  • Querleu D., Cibula D., Abu-Rustum N.R. (2017) 2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy. Ann. Surg. Oncol., 24(11): 3406–3412. doi: 10.1245/s10434-017-6031-z.
  • Ramirez P.T., Abu-Rustum N.R., Euscher E. et al. (2019) Conservative management of cervical cancer in pregnancy. Int. J. Gynecol. Cancer, pii: ijgc-2018-000187. DOI: 10.1136/ijgc-2018-000187.
  • Rema P., Mathew A.P., Suchetha S. et al. (2017) Salvage Surgery for Cervical Cancer Recurrences. Indian J. Surg. Oncol., 8(2): 146–149. DOI: 10.1007/s13193-015-0472-2.
  • Sawaya G.F., Smith-McCune K., Kuppermann M. (2019) Cervical Cancer Screening: More Choices in 2019. JAMA, 321(20): 2018–2019. DOI: 10.1001/jama.2019.4595.
  • Union for International Cancer Control (UICC) (2016) Eighth edition of the UICC TNM Classification of Malignant Tumours.
  • Vergote I., Magrina J.F., Zanagnolo V. et al. (2020) The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. J. Minim. Invasive Gynecol., 27(2): 462–463. DOI: 10.1016/j.jmig.2019.09.767.
  • Wang A., Cui G., Jin C. et al. (2019) Multicenter research on tumor and pregnancy outcomes in patients with early-stage cervical cancer after fertility-sparing surgery. J. Int. Med. Res., 47(7): 2881–2889. DOI: 10.1177/0300060519845974.
  • Wipperman J., Neil T., Williams T. et. al. (2018) Cervical Cancer: Evaluation and Management. Am. Fam. Physician, 97(7): 449–454.
  • Wright J.D., Matsuo K., Huang Y. et al. (2018) Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet. Gynecol., 134(1): 49–57. DOI: 10.1097/AOG.0000000000003311.
  • Yu H., Zhang L., Li D. et al. (2019) Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy achieved the equivalent survival compared with concurrent chemoradiotherapy in cervical cancer patients with intermediate-risk. Jpn. J. Clin. Oncol., 49(8): 714–718. DOI: 10.1093/jjco/hyz057.
  • Zhang Q., Li W., Kanis M.J. et al. (2017) Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis. Oncotarget., 8(28): 46580–46592. DOI: 10.18632/oncotarget.16233.
  • Zigras T., Lennox G., Willows K. et al. (2017) Early Cervical Cancer: Current Dilemmas of Staging and Surgery. Curr. Oncol. Rep., 19(8): 51. DOI: 10.1007/s11912-017-0614-5.